Universal Dual Specificity Cd19 And Cd20 Or Cd22 Car-T Cells
B-Cell Non-Hodgkin Lymphoma
Chinese PLA General HospitalCell therapyPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
317 Active assets in the B-Cell Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINDESINE Children's Cancer Group, China | Phase 4 | BBB |
cc-5013 Shanghai Junshi Bioscience Co., Ltd. | Phase 4 | BBB |
Odronextamab University of Birmingham | Phase 3 | BBB |
Cytosin-Arabinosid Children's Cancer Group, China | Phase 4 | BBB |
METHOTREXATE Children's Cancer Group, China | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Universal Dual Specificity Cd19 And Cd20 Or Cd22 Car-T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →